Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.10 - $11.60
Previous CloseN/A
Volume87.32K
Average Volume (3M)362.54K
Market Cap
$123.96M
Enterprise Value$526.14M
Total Cash (Recent Filing)-$9.62M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.51
Next Earnings
May 19, 2025EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding52,748,344
10 Day Avg. Volume382,339
30 Day Avg. Volume362,538
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap4.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.19
Forecast
1Y Price Target
$9.00Price Target Upside282.98% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Kodiak Sciences News
---
Bulls Say, Bears Say
Bulls Say
Investor InterestInvestors are starting to come back to Kodiak Sciences, viewing the stock as very cheap with lots of room to grow.
Potential ApprovalThere is an expectation for potential approval across wet AMD, retinal vein occlusion, and diabetic retinopathy indications.
Strategic PositioningThe company has taken appropriate strategic steps to position the ABCD platform for its best shots on goal.
Bears Say
Adverse EventsInvestors are reminded of the prior late-stage failures for tarcocimab in the Phase 3 GLEAM and GLIMMER trials in DME, unexpected increase in cataract AEs over time for tarcocimab, and the Phase 2b/3 DAZZLE trial failure in wet AMD.
Past Trial FailuresKodiak continues to turn the page from its previous late-stage tarcocimab setbacks, including the Phase 3 GLEAM and GLIMMER trial failures in DME and the Phase 2b/3 DAZZLE trial failure in wet AMD.
---
Ownership Overview
34.81% Insiders
8.68% Mutual Funds
<0.01% Other Institutional Investors
48.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $2.10 and its highest was $11.60 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $123.96M.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is May 19, 2025 which is in 42 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Mar 27, 2025. The company reported -$0.84 earnings per share for the quarter, beating the consensus estimate of -$0.883 by $0.043.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -0.92.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 52,748,344 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$0.84 in its last earnings report, beating expectations of -$0.883. Following the earnings report the stock price went down -4.902%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
---
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.00 (282.98% Upside)
$9.00 (282.98% Upside)
Blogger Sentiment
Neutral
KOD Sentiment 50%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 112.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.40%
12-Months-Change
Fundamentals
Return on Equity
-84.70%
Trailing 12-Months
Asset Growth
-30.00%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
---
KOD Stock 12 Month Forecast
Average Price Target
$9.00
▲(282.98% Upside)
Technical Analysis
Ocular Therapeutix
―
RegenXBio
―
Editas Medicine
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Best Analysts Covering KOD
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+52.48%
reiterated a sell rating 10 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +52.48% per trade.
---